PIERRE FABRE MEDICAMENT

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Locally Advanced or Metastatic Solid Tumors

Interventions: Biological: W0180
Drug: Pembrolizumab

First Posted Date: 2020-09-25

Last Posted Date: 2024-01-31

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 33

Registration Number: NCT04564417

Locations: 🇫🇷
IGR, Villejuif, Villejuif, France
🇪🇸
CUN, Pamplona, Pamplona, Spain
🇫🇷
IUCT, Toulouse, Toulouse, France

and more 2 locations

A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

Completed

Conditions: Metastatic Colorectal Cancer
BRAF V600E Mutation Positive

Interventions: Other: Non Interventional study

First Posted Date: 2020-03-23

Last Posted Date: 2024-07-15

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 274

Registration Number: NCT04317599

Locations: 🇧🇪
UZ Leuven, Leuven, Belgium
🇦🇹
Barmherzige Brüder Krankenhaus St. Veit/Glan., St. Veit/Glan, Austria
🇦🇹
Medizinische Universität Wien, Vienna, Austria

and more 31 locations

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine 1250 mg/m²
Drug: oral vinorelbine
Drug: Gemcitabine 1000 mg/m²
Drug: Capecitabine
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2019-03-22

Last Posted Date: 2024-04-30

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 152

Registration Number: NCT03887130

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Phase 2

Completed

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer

Interventions: Drug: encorafenib
Drug: Binimetinib
Drug: Cetuximab

First Posted Date: 2018-10-02

Last Posted Date: 2024-02-02

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 95

Registration Number: NCT03693170

Locations: 🇫🇷
AP-HM CHU Timone, Marseille, France
🇫🇷
ICO- Site René Gauducheau, Saint-Herblain, France
🇫🇷
Hôpital Europeen Georges Pompidou, Paris, France

and more 37 locations

A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: W0101 - Cohort A1
Drug: W0101 - Cohort A2
Drug: W0101 - Expansion Phase

First Posted Date: 2017-10-20

Last Posted Date: 2024-12-10

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 316

Registration Number: NCT03316638

Locations: 🇫🇷
IUCT, Toulouse, France
🇫🇷
IGR, Villejuif, France
🇪🇸
VHIO, Barcelona, Spain

EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS

Phase 2

Withdrawn

Conditions: Venous Disease Classification (CEAP): C2 or C3

Interventions: Drug: placebo CYCLO 3 ® FORT
Drug: MPFF
Drug: CYCLO 3 ® FORT
Drug: placebo MPFF

First Posted Date: 2016-09-20

Last Posted Date: 2017-02-20

Lead Sponsor: Pierre Fabre Medicament

Registration Number: NCT02907320

Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia

Phase 1

Terminated

Conditions: Iron Deficiency Anemia

Interventions: Drug: V0355

First Posted Date: 2015-08-10

Last Posted Date: 2016-09-28

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 29

Registration Number: NCT02518568

Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction

Phase 4

Completed

Conditions: Alveolar Osteitis

Interventions: Drug: Placebo
Drug: DC071

First Posted Date: 2015-03-09

Last Posted Date: 2016-03-09

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 414

Registration Number: NCT02382809

Assessment of V0018 1.5 mg Effect on Craving

Phase 2

Completed

Conditions: Smoking

Interventions: Drug: V0018
Drug: Placebo

First Posted Date: 2015-02-09

Last Posted Date: 2015-04-21

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 30

Registration Number: NCT02359201

Assessment of V0018 2.5 mg Effect on Craving

Phase 2

Completed

Conditions: Healthy Highly Dependant Smokers

Interventions: Drug: V0018
Drug: Placebo

First Posted Date: 2015-02-06

Last Posted Date: 2015-10-08

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 45

Registration Number: NCT02357888

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy